The Eugenics Movement in Retrospect
By Rob DeSalle,
Natural History
| 12. 11. 2021
Despite warnings by biologists and geneticists, eminent individuals and venerable institutions helped promote a false theory that led to sterilizations and genocide.
One hundred years ago, the Second International Congress of Eugenics was held from September 22-28, 1921, at the American Museum of Natural History (AMNH) in New York City. The assembly opened to enthusiastic fanfare and positive media attention. Alexander Graham Bell (1847-1922) was the honorary president. On the first evening, paleontologist and museum president, Henry Fairfield Osborn (1857-1935), opened the scientific portion of the Congress with a welcoming address that set a hopeful tone for the meeting—one of discovery and high-quality scientific presentations. Science magazine printed the address in its entirety. In a paper published in The Eugenics Review, Clarence Cook Little (1888-1971), then at the Carnegie Institution of Washington, summarized the goals of the meeting and the speaking schedules.
The Second Congress had four sections entitled “Human and Comparative Heredity,” “Eugenics and the Family,” “Human Racial Differences,” and “Eugenics and the State.” AMNH mounted an exhibition for the event, called the “Exhibition of Eugenics.” Henry Hamilton Laughlin (1880-1943), superintendent of the Eugenics Record Office at the Cold Spring Harbor Laboratory on Long Island, NY, edited a book-size account...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...